Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 September 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 189 pages)

 

Export 7 results:
Author [ Title(Desc)] Type Year
Filters: Author is Schlienger, R.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
A. Ruigomez, Brauer, R., Rodriguez, L. A., Huerta, C., Requena, G., Gil, M., de Abajo, F., Downey, G., Bate, A., Tepie, M. F., de Groot, M., Schlienger, R., Reynolds, R., and Klungel, O., “Ascertainment of acute liver injury in two European primary care databases”, Eur J Clin Pharmacol, vol. 70, pp. 1227-35, 2014.
R. Williams, Kothny, W., Serban, C., Lopez-Leon, S., de Vries, F., and Schlienger, R., “Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00084, 2019.
C
R. Williams, de Vries, F., Kothny, W., Serban, C., Lopez-Leon, S., Chu, C., and Schlienger, R., “Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study”, Diabetes Obes Metab, vol. 19, pp. 1473-1478, 2017.
H
G. Requena, Huerta, C., Gardarsdottir, H., Logie, J., Gonzalez-Gonzalez, R., Abbing-Karahagopian, V., Miret, M., Schneider, C., Souverein, P. C., Webb, D., Afonso, A., Boudiaf, N., Martin, E., Oliva, B., Alvarez, A., de Groot, M. C., Bate, A., Johansson, S., Schlienger, R., Reynolds, R., Klungel, O. H., and de Abajo, F. J., “Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project”, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 66-78, 2016.
I
M. Schuerch, Gasse, C., Robinson, N. J., Alvarez, Y., Walls, R., Mors, O., Christensen, J., Hesse, U., de Groot, M., Schlienger, R., Reynolds, R., Klungel, O., and de Vries, F., “Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR)”, Pharmacoepidemiol Drug Saf, vol. 25 Suppl 1, pp. 142-55, 2016.
M
A. Afonso, Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana, E., Souverein, P., Wang, Y., Korevaar, J. C., Hasford, J., Reynolds, R., de Groot, M. C., Schlienger, R., Klungel, O., and Rottenkolber, M., “A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction”, Eur J Clin Pharmacol, vol. 72, pp. 1105-16, 2016.
P
R. Williams, Kothny, W., Serban, C., Lopez-Leon, S., and Schlienger, R., “Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00052, 2019.
[Page last reviewed 6 September 2019]